Issue Archive

[Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer’s disease.] [Ariticle in Chinese]

WANG Xiao-Hui, YANG Wei, QI Jin-Shun^*

Department of Physiology, Key Laboratory for Cellular Physiology of Ministry of Education, Shanxi Medical University, Taiyuan 030001, China

Abstract

There is a close correlation between type 2 diabetes mellitus (T2DM) and Alzheimer’s disease (AD) in the course ofpathophysiological processes. The neuroprotective action of glucagon-like peptide 1 (GLP-1), a latest drug for clinical treatment ofT2DM, is being more deeply investigated at present, and a novel therapeutic strategy for AD with GLP-1 has been proposed boldly.This review mainly discussed the correlation of pathogenesis between T2DM and AD, the synthesis and secretion of GLP-1, thedistribution and physiological effects of GLP-1 receptor in the brain, and the progresses on the study of GLP-1 in the treatment of AD.

Key words: glucagon-like peptide 1; neuroprotection; Alzheimer's disease; type 2 diabetes mellitus; amyloid-β peptide

Received: 2010-07-14　　Accepted: 2010-08-03

Corresponding author: 祁金顺　　E-mail: jinshunqi2006@yahoo.com

Citing This Article：

WANG Xiao-Hui, YANG Wei, QI Jin-Shun. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer’s disease.] [Ariticle in Chinese] . Acta Physiol Sin 2010; 62 (5): 398-406 (in Chinese with English abstract).